Breast cancer is the most frequent malignancy in women worldwide and is curable in~ 70–
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …

Guidelines promote high quality cancer care. Rehabilitation recommendations in oncology
guidelines have not been characterized and may provide insight to improve integration of …

Background Immunotherapy in combination with chemotherapy has shown promising
efficacy across many different tumour types. We report the prespecified second interim …

PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
recurrence or have distant recurrence with currently available standard therapies. However …

Background Patients who have residual invasive breast cancer after receiving neoadjuvant
chemotherapy plus human epidermal growth factor receptor 2 (HER2)–targeted therapy …

Background Unresectable locally advanced or metastatic triple-negative (hormone-receptor–
negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer is …

Purpose: Up to 30% of patients with breast cancer relapse after primary treatment. There are
no sensitive and reliable tests to monitor these patients and detect distant metastases before …

Background Deep learning (DL) algorithms are gaining extensive attention for their excellent
performance in image recognition tasks. DL models can automatically make a quantitative …

Background ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine
kinase inhibitor, significantly improves 2-year invasive disease-free survival after …

Highlights•Breast cancer in young women should be treated based on stage and biology of
disease.•Management of breast cancer in young women requires special considerations …